Drug Type Small molecule drug |
Synonyms Diponecaftor, PTI-428/PTI-808/PTI-801, PTI-NC-733 |
Target |
Action stimulants |
Mechanism CFTR stimulants(Cystic fibrosis transmembrane conductance regulator stimulants) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC27H27NO5 |
InChIKeyQUDOHCFOJCNKPK-QGZVFWFLSA-N |
CAS Registry2095064-05-2 |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Cystic Fibrosis | Phase 2 | Belgium | 03 Jun 2024 | |
| Cystic Fibrosis | Phase 2 | France | 03 Jun 2024 | |
| Cystic Fibrosis | Phase 2 | Germany | 03 Jun 2024 | |
| Cystic Fibrosis | Phase 2 | Italy | 03 Jun 2024 | |
| Cystic Fibrosis | Phase 2 | Netherlands | 03 Jun 2024 | |
| Cystic Fibrosis | Phase 2 | Portugal | 03 Jun 2024 | |
| Cystic Fibrosis | Phase 2 | Spain | 03 Jun 2024 | |
| Cystic Fibrosis | Phase 2 | Sweden | 03 Jun 2024 | |
| Cystic Fibrosis | Phase 2 | United Kingdom | 03 Jun 2024 |





